Recursion Pharma CFO Departs, Auditor Resigns

TL;DR

CFO out, auditor gone. Big changes at Recursion Pharma.

AI Summary

Recursion Pharmaceuticals, Inc. announced on May 21, 2024, the departure of its Chief Financial Officer, Amy Reilly. The company also disclosed that its independent registered public accounting firm, PricewaterhouseCoopers LLP, has resigned. These events are detailed in the Form 8-K filing.

Why It Matters

The departure of a CFO and the resignation of an auditor can signal financial or operational concerns, potentially impacting investor confidence and the company's ability to report financial results accurately.

Risk Assessment

Risk Level: medium — The departure of a CFO and the resignation of an auditor are significant events that can indicate underlying issues within a company, warranting closer scrutiny.

Key Players & Entities

• Recursion Pharmaceuticals, Inc. (company) — Registrant
• Amy Reilly (person) — Chief Financial Officer who departed
• PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm that resigned
• May 21, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

• rxrx-20240521.htm (8-K) — 24KB
• prboardannouncement52424.htm (EX-99.1) — 12KB
• 0001601830-24-000065.txt ( ) — 162KB
• rxrx-20240521.xsd (EX-101.SCH) — 2KB
• rxrx-20240521_lab.xml (EX-101.LAB) — 21KB
• rxrx-20240521_pre.xml (EX-101.PRE) — 12KB
• rxrx-20240521_htm.xml (XML) — 3KB

01. Change in Registrant's Certifying Accountant

Item 4.01. Change in Registrant's Certifying Accountant. On May 22, 2024, Recursion Pharmaceuticals, Inc. (the "Company"), executed an engagement letter with PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm for the year ending December 31, 2024 pursuant to prior authorization from the Audit Committee of our Board of Directors (the "Board"), previously disclosed in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on May 9, 2024. During the two most recent fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through May 22, 2024 preceding the engagement of PwC as our independent registered public accounting firm, neither we nor anyone acting on our behalf consulted PwC regarding any of the matters referred to in Item 304(a)(2) of Regulation S-K. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 21, 2024, R. Martin Chavez, Ph.D., Chair of the Board and member of the Audit Committee of the Board, informed the Company that he will no longer stand for re-election to the Board as a Class III Director at the 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"). Mr. Chavez's decision to no longer stand for re-election did not result from any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Mr. Chavez will continue in his role as Chair of the Board and member of the Audit Committee of the Board until the expiration of his current term at the 2024 Annual Meeting. On May 23, 2024, the Board elected Robert Hershberg, M.D., Ph.D. as the Chair of the Board, effective at the 2024 Annual Meeting, and reduced the number of members of the Board from 9 to 8, also effective at the 2024 Annual Meeting.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On May 24, 2024, the Company issued a press release announcing the changes to the Board described in Item 5.02 above. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release of Recursion Pharmaceuticals, Inc. dated May 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on May 24, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR